Sign In
Buy SITC
$4.88
-0.0500 (-1.01%)
At Close: Jun 03, 2026
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
10:00am, Thursday, 07'th Nov 2024
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 0
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10:00am, Thursday, 07'th Nov 2024
Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotech
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
09:02am, Thursday, 07'th Nov 2024
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
10:47am, Wednesday, 06'th Nov 2024
AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio p
SAN JOSE, Calif. , Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno
BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING
07:00am, Wednesday, 06'th Nov 2024
MINNEAPOLIS , Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to pers
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the SITC 39th Annual Meeting.
NEEDHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
SITE Centers Q3 OFFO & Revenues Miss Estimates, Stock Falls
02:56pm, Thursday, 31'st Oct 2024
SITC's third-quarter results reflect a year-over-year fall in revenues and base rent per square foot.
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1 stu
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
08:00am, Thursday, 31'st Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Compared to Estimates, SITE Centers Corp. (SITC) Q3 Earnings: A Look at Key Metrics
10:35am, Wednesday, 30'th Oct 2024
While the top- and bottom-line numbers for SITE Centers Corp. (SITC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key me
SITE CENTERS CORP. (SITC) Q3 FFO and Revenues Miss Estimates
10:20am, Wednesday, 30'th Oct 2024
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.81 per share, missing the Zacks Consensus Estimate of $0.87 per share.
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
09:15am, Wednesday, 30'th Oct 2024
Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation
